Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Ovarian Cancer
Interventions: flutamide; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 83 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Sepsis
Interventions: Sepsis; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke, TIA, Ischemic Stroke, Ischemic
Interventions: Medical Imaging; Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Bladder Cancer
Interventions: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 566
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 342 more

Conditions: Breast Cancer
Interventions: gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration; Genetic · Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Myeloma
Interventions: Propranolol; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Anxiety, Somatic Symptom Disorder
Interventions: Emotional Awareness & Expression Therapy, Mindfulness Meditation Training; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Milk Expression
Interventions: Manual Expression of Breastmilk; Procedure
Lead sponsor: St. Louis Children's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Lavender essential oil-based product system; Other
Lead sponsor: dōTERRA International; Industry
Eligibility: 35 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Healthy, Breast Pumping
Interventions: Prototypes of breast shield and Freedom Double Electric Breast Pump; Device
Lead sponsor: Momtech Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Healthy Adult Volunteers
Interventions: Supplement A followed by Supplement B, Supplement B followed by Supplement A; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hepatitis C
Interventions: Interferon alpha; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Hypertrophic Scars
Interventions: Fraxel Repair - Fractional Laser treatment; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: ELU001; Drug
Lead sponsor: Elucida Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more

Conditions: Childhood Cancer
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Vehicle cream; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cardiac Transplant Disorder
Interventions: Endomyocardial biopsy; Procedure
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Dallas, Texas • Salt Lake City, Utah + 1 more

Conditions: Pregnancy Related, Breast Feeding, Milk Expression, Breast
Interventions: Antenatal milk expression, Education handouts; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
Interventions: Tamoxifen; Drug
Lead sponsor: AC Camargo Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Asthma
Interventions: Inhaled fluticasone 500 ug BID for 8 weeks; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Skin Laxity
Interventions: Ultherapy Treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Phoenix, Arizona • Mequon, Wisconsin

Conditions: Autism
Interventions: Not listed
Lead sponsor: SynapDx; Industry
Eligibility: 18 Months to 60 Months
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Scottsdale, Arizona • Long Beach, California • Sacramento, California + 15 more

Conditions: Ocular Inflammatory Disease, Uveitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 6 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

Expression Profiles of Integrin αDβ2 on Neutrophils in Sepsis

Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis

Cell Lines From High-Risk Breast Tissue

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Biomarkers in Blood Samples From Older Breast Cancer Survivors

Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients

Student Anxiety & Stress Study

The Merit Study (Manual Expression pRemature InfanTs)

Lavender Essential Oil-based Product System for Sleep

Engineering Evaluation of a Breast Pump Device

Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers

Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes

Gene Expression During Surgical Scar Remodeling by Fractional Photothermolysis

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Feasibility of Isolating P16 Expression

Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

Antenatal Milk Expression in Nulliparous Pregnant People

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma

Gene Expression Following Ultherapy® Treatment

SynapDx Autism Gene Expression Analysis Study (STORY)

Differences in Genes and Proteins in Active and Controlled Uveitis